Plain-English translation of NCT06492863 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing FT-003, a new gene therapy designed to treat wet age-related macular degeneration (wet AMD), a condition that causes vision loss in older adults. Currently, people with wet AMD need eye injections every 4 to 12 weeks to maintain their vision. The medication aims to provide long-lasting improvement so that patients may need fewer or no injections over time, reducing the burden of ongoing treatment.
Many people with wet AMD miss or skip their regular eye injections because the frequent visits are hard to manage, which leads to preventable vision loss. This trial exists to see if the new treatment can work for longer periods, making it easier for patients to stick with their care and protect their sight.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive an injection of the medication into your eye. The trial will test three different doses to find the safest and most effective level. You'll have regular follow-up visits where doctors will check your vision and eye health to see how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data ยท Jun 9, 2026 ยท Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Frontera Therapeutics
Collaborators
Tianjin Medical University Eye Hospital, The First Affiliated Hospital of Soochow University
Enrollment target
~78 participants
Started
August 2023
Primary completion
October 2024
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
50 Years โ 80 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Xinyan Li
Tianjin Medical University Eye Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.